PineBridge Investments’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $379K | Sell |
720
-8,565
| -92% | -$4.8M | ﹤0.01% | 496 |
|
|
2026
Q1 | $5.22M | Sell |
9,285
-9,186
| -50% | -$5.89M | 0.04% | 224 |
|
|
2025
Q4 | $12.5M | Sell |
18,471
-31,029
| -63% | -$21.1M | 0.09% | 158 |
|
|
2025
Q3 | $31.6M | Sell |
49,500
-37,606
| -43% | -$22.8M | 0.23% | 96 |
|
|
2025
Q2 | $46.7M | Sell |
87,106
-21,258
| -20% | -$10.2M | 0.37% | 59 |
|
|
2025
Q1 | $45.5M | Buy |
108,364
+19,174
| +21% | +$8.33M | 0.36% | 57 |
|
|
2024
Q4 | $36.9M | Sell |
89,190
-1,450
| -2% | -$636K | 0.28% | 78 |
|
|
2024
Q3 | $45.8M | Sell |
90,640
-15,765
| -15% | -$7.66M | 0.34% | 63 |
|
|
2024
Q2 | $51.8M | Buy |
106,405
+6,763
| +7% | +$3.4M | 0.42% | 49 |
|
|
2024
Q1 | $53.8M | Buy |
99,642
+5,919
| +6% | +$3.23M | 0.43% | 45 |
|
|
2023
Q4 | $52M | Sell |
93,723
-10,995
| -10% | -$5.16M | 0.48% | 41 |
|
|
2023
Q3 | $45.8M | Buy |
104,718
+20,547
| +24% | +$10.2M | 0.51% | 37 |
|
|
2023
Q2 | $42.3M | Buy |
84,171
+44,874
| +114% | +$21.5M | 0.46% | 46 |
|
|
2023
Q1 | $19.7M | Buy |
39,297
+19,074
| +94% | +$9.13M | 0.22% | 124 |
|
|
2022
Q4 | $8.25M | Buy |
20,223
+6,064
| +43% | +$2.35M | 0.1% | 206 |
|
|
2022
Q3 | $4.61M | Buy |
14,159
+412
| +3% | +$151K | 0.06% | 266 |
|
|
2022
Q2 | $4.82M | Sell |
13,747
-11,880
| -46% | -$4.84M | 0.06% | 261 |
|
|
2022
Q1 | $14M | Buy |
25,627
+1,078
| +4% | +$567K | 0.15% | 161 |
|
|
2021
Q4 | $16.2M | Buy |
24,549
+3,955
| +19% | +$2.48M | 0.17% | 149 |
|
|
2021
Q3 | $12.8M | Buy |
20,594
+1,601
| +8% | +$1.08M | 0.15% | 155 |
|
|
2021
Q2 | $12M | Buy |
18,993
+853
| +5% | +$471K | 0.14% | 179 |
|
|
2021
Q1 | $8.88M | Buy |
18,140
+18,066
| +24,414% | +$9.05M | 0.11% | 216 |
|
|
2020
Q4 | $37K | Buy |
+74
| New | +$33.1K | ﹤0.01% | 599 |
|
|
2020
Q2 | – | Sell |
-37,992
| Closed | -$9.2M | – | 711 |
|
|
2020
Q1 | $9.2M | Buy |
37,992
+33,468
| +740% | +$8.73M | 0.22% | 121 |
|
|
2019
Q4 | $1.18M | Sell |
4,524
-1,220
| -21% | -$321K | 0.02% | 522 |
|
|
2019
Q3 | $1.56M | Buy |
+5,744
| New | +$1.6M | 0.03% | 523 |
|
|
2018
Q4 | – | Sell |
-12
| Closed | -$3K | – | 1096 |
|
|
2018
Q3 | $3K | Sell |
12
-332
| -97% | -$80.6K | ﹤0.01% | 1081 |
|
|
2018
Q2 | $75K | Buy |
+344
| New | +$70.9K | ﹤0.01% | 954 |
|
|
2018
Q1 | – | Sell |
-48
| Closed | -$8K | – | 1131 |
|
|
2017
Q4 | $8K | Sell |
48
-8,936
| -99% | -$1.41M | ﹤0.01% | 1015 |
|
|
2017
Q3 | $1.4M | Sell |
8,984
-1,562
| -15% | -$247K | 0.03% | 427 |
|
|
2017
Q2 | $1.7M | Buy |
10,546
+1,315
| +14% | +$214K | 0.04% | 316 |
|
|
2017
Q1 | $1.43M | Sell |
9,231
-14,417
| -61% | -$1.99M | 0.04% | 389 |
|
|
2016
Q4 | $2.77M | Buy |
23,648
+5,677
| +32% | +$648K | 0.08% | 198 |
|
|
2016
Q3 | $2.03M | Buy |
+17,971
| New | +$1.89M | 0.09% | 188 |
|
Other funds holding IDXX
PineBridge Investments's IDXX Position: Q2 2026 in Review
PineBridge Investments reduced its Idexx Laboratories (IDXX) stake by 92% in Q2 2026, selling an estimated $4.8M and leaving 720 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #496.
PineBridge Investments first reported a position in IDXX in Q3 2016 and has held it in 34 quarters since. The position peaked at $53.8M in Q1 2024. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- PineBridge Investments held 720 shares of Idexx Laboratories worth $379K as of Q2 2026.
- PineBridge Investments sold 8,565 Idexx Laboratories shares in Q2 2026, an estimated $4.8M.
- Idexx Laboratories made up ﹤0.01% of PineBridge Investments's portfolio in Q2 2026, its #496 holding.
- PineBridge Investments first reported a position in Idexx Laboratories in Q3 2016 and has held it in 34 quarters since.
- PineBridge Investments's Idexx Laboratories position peaked at $53.8M in Q1 2024.
- 1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on PineBridge Investments's 13F filing for Q2 2026, filed 14 Aug 2026.